To include your compound in the COVID-19 Resource Center, submit it here.
Cleave began a 2-stage, open-label, U.S. Phase I trial of oral CB-5083 in up to 60
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury